menu
    • menu
    [{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"STZ eyetrial","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil Hydrochloride","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)||Inosine-5\\'-monophosphate dehydrogenase (IMPDH)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ STZ eyetrial","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ STZ eyetrial"}]

    Find Clinical Drug Pipeline Developments & Deals for Mycophenolate Mofetil Hydrochloride

    Menu

    Mycophenolate Mofetil Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycophenolate Mofetil Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : STZ eyetrial

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Myfortic for the Treatment of Non-infectious Intermediate Uveitis

                            Details : Myfortic is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Uveitis, Intermediate.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 25, 2010

                            Lead Product(s) : Mycophenolate Mofetil Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : STZ eyetrial

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth